These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 29398545)

  • 1. Structural development of tetrachlorophthalimides as liver X receptor β (LXRβ)-selective agonists with improved aqueous solubility.
    Nomura S; Endo-Umeda K; Fujii S; Makishima M; Hashimoto Y; Ishikawa M
    Bioorg Med Chem Lett; 2018 Feb; 28(4):796-801. PubMed ID: 29398545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists.
    Nomura S; Endo-Umeda K; Makishima M; Hashimoto Y; Ishikawa M
    ChemMedChem; 2016 Oct; 11(20):2347-2360. PubMed ID: 27690261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists.
    Motoshima K; Noguchi-Yachide T; Sugita K; Hashimoto Y; Ishikawa M
    Bioorg Med Chem; 2009 Jul; 17(14):5001-14. PubMed ID: 19539483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype.
    Lund EG; Peterson LB; Adams AD; Lam MH; Burton CA; Chin J; Guo Q; Huang S; Latham M; Lopez JC; Menke JG; Milot DP; Mitnaul LJ; Rex-Rabe SE; Rosa RL; Tian JY; Wright SD; Sparrow CP
    Biochem Pharmacol; 2006 Feb; 71(4):453-63. PubMed ID: 16325781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
    Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
    Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.
    Kick E; Martin R; Xie Y; Flatt B; Schweiger E; Wang TL; Busch B; Nyman M; Gu XH; Yan G; Wagner B; Nanao M; Nguyen L; Stout T; Plonowski A; Schulman I; Ostrowski J; Kirchgessner T; Wexler R; Mohan R
    Bioorg Med Chem Lett; 2015 Jan; 25(2):372-7. PubMed ID: 25435151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches.
    Chen M; Yang F; Kang J; Gan H; Yang X; Lai X; Gao Y
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29867043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying selective agonists targeting LXRβ from terpene compounds of alismatis rhizoma.
    Lin C; Li J; Wu C; Bao J
    J Mol Model; 2021 Feb; 27(3):91. PubMed ID: 33616795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.
    Kirchgessner TG; Sleph P; Ostrowski J; Lupisella J; Ryan CS; Liu X; Fernando G; Grimm D; Shipkova P; Zhang R; Garcia R; Zhu J; He A; Malone H; Martin R; Behnia K; Wang Z; Barrett YC; Garmise RJ; Yuan L; Zhang J; Gandhi MD; Wastall P; Li T; Du S; Salvador L; Mohan R; Cantor GH; Kick E; Lee J; Frost RJ
    Cell Metab; 2016 Aug; 24(2):223-33. PubMed ID: 27508871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Discovery of potential LXRβ agonists from Chinese herbs using molecular simulation methods].
    Luo GG; Lu F; Qiao LS; Li Y; Zhang YL
    Zhongguo Zhong Yao Za Zhi; 2016 Aug; 41(16):3065-3071. PubMed ID: 28920350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of phthalimide-based fluorescent liver x receptor antagonists.
    Kishida K; Aoyama A; Hashimoto Y; Miyachi H
    Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1525-8. PubMed ID: 21048348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.
    Hu B; Unwalla RJ; Goljer I; Jetter JW; Quinet EM; Berrodin TJ; Basso MD; Feingold IB; Nilsson AG; Wilhelmsson A; Evans MJ; Wrobel JE
    J Med Chem; 2010 Apr; 53(8):3296-304. PubMed ID: 20350005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural development of liver X receptor (LXR) antagonists derived from thalidomide-related glucosidase inhibitors.
    Noguchi-Yachide T; Miyachi H; Aoyama H; Aoyama A; Makishima M; Hashimoto Y
    Chem Pharm Bull (Tokyo); 2007 Dec; 55(12):1750-4. PubMed ID: 18057753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structurally Selective Mechanism of Liver X Receptor Ligand:
    Ding P; Chen Z; Chen H; Zhang Z; Liu Z; Yan X; Zhou H; Gu Q; Li C; Xu J
    J Chem Inf Model; 2019 Jul; 59(7):3277-3290. PubMed ID: 31192592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.
    Molteni V; Li X; Nabakka J; Liang F; Wityak J; Koder A; Vargas L; Romeo R; Mitro N; Mak PA; Seidel HM; Haslam JA; Chow D; Tuntland T; Spalding TA; Brock A; Bradley M; Castrillo A; Tontonoz P; Saez E
    J Med Chem; 2007 Aug; 50(17):4255-9. PubMed ID: 17665897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells.
    DiBlasio-Smith EA; Arai M; Quinet EM; Evans MJ; Kornaga T; Basso MD; Chen L; Feingold I; Halpern AR; Liu QY; Nambi P; Savio D; Wang S; Mounts WM; Isler JA; Slager AM; Burczynski ME; Dorner AJ; LaVallie ER
    J Transl Med; 2008 Oct; 6():59. PubMed ID: 18925943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.
    Hu B; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wihelmsson A; Nambi P; Wrobel J
    Bioorg Med Chem; 2009 May; 17(10):3519-27. PubMed ID: 19394832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in Aqueous Solubility of Retinoic Acid Receptor (RAR) Agonists by Bending the Molecular Structure.
    Hiramatsu M; Ichikawa Y; Tomoshige S; Makishima M; Muranaka A; Uchiyama M; Yamaguchi T; Hashimoto Y; Ishikawa M
    Chem Asian J; 2016 Aug; 11(15):2210-7. PubMed ID: 27378357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists.
    Marinozzi M; Castro Navas FF; Maggioni D; Carosati E; Bocci G; Carloncelli M; Giorgi G; Cruciani G; Fontana R; Russo V
    J Med Chem; 2017 Aug; 60(15):6548-6562. PubMed ID: 28741954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.
    Hu B; Bernotas R; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wilhelmsson A; Nambi P; Evans M; Wrobel J
    Bioorg Med Chem Lett; 2010 Jan; 20(2):689-93. PubMed ID: 19962892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.